Thyroid GuidePX®: A smarter system for thyroid cancer care Although survival rates are high, thyroid cancer patients often face unnecessary treatments due to the reliance on inaccurate risk assessment tools. The Thyroid GuidePx® test offers a solution. Oliver Bathe explains why policymakers and health leaders should support molecular risk testing. Papillary thyroid cancer (PTC) is among the most commonly diagnosed cancers in North America. Though survival rates are high, many patients undergo more treatment than necessary. The current system often relies on imprecise tools to assess risk, leading to aggressive care even when the cancer poses minimal threat. This mismatch creates unnecessary complications, higher costs, and avoidable burdens for patients and healthcare systems alike. At the core of this challenge is the inability to accurately assess recurrence risk before treatment.
Oliver Bathe (Thu,) studied this question.